Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, today announced the release of the minimum viable product version of iSTRYM, its digital therapeutics platform (“DTx”) for psychedelics, into partner clinics across North America. According to the update, the company will begin full commercial deployment to all clinics in the first quarter of 2022. MINDCURE intends to target psychedelic clinics initially and to then expand to integrated clinics, both traditional and psychedelic, and eventually to the broader mental health market. The company forecasts 150 clinics in Canada, the U.S. and Europe utilizing iSTRYM by the fourth quarter of 2022. “MINDCURE created iSTRYM with the goal of unlocking value for researchers, therapists and ultimately patients in need,” said MINDCURE Advisor Dr. John Brownstein. “I believe there’s a real opportunity to improve mental health treatments through a better understanding of patient and research data, and that this platform can be a valuable resource for the entire psychedelics industry.”
To view the full press release, visit https://ibn.fm/JtfXl
About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit www.MindCure.com.
NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.